



PTO/SB/08 (2/92)

Sheet 1 of 4

Form PTO-1449

Docket No. GZ 2063.10

Appl. No. 09/920,480

INFORMATION DISCLOSURE  
STATEMENT

Applicant(s)

Charles A. NICOLETTE

Filing Date: August 1, 2001

Group Art Unit: 1644

(use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
MD	1.	07/28/87	4,683,195	Mullis et al.			
MD	2.	07/28/87	4,683,202	Mullis			
MD	3.	06/28/88	4,754,065	Levenson et al.			
MD	4.	01/24/89	4,800,159	Mullis et al.			
MD	5.	08/08/95	5,440,013	Kahn			
	6.	11/17/98	5,837,249	Heber-Katz et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
MD	7.	08/23/95	0 668 350 A1	Nobel			
MD	8.	08/01/96	WO 96/23060	Cohen et al.			

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
MD	9.	Al-Ramadi, B.K. et al. (1992) "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" <i>J. Immunol.</i> <b>155</b> (2):662-673.
MD	10.	Altman, J.D. et al. (1996) "Phenotypic analysis of antigen-specific T lymphocytes" <i>Science</i> <b>274</b> (5284):94-96.
MD	11.	Bakker, A.B.H. et al. (1997) "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope" <i>Int. J. Cancer</i> <b>70</b> :302-309.
MD	12.	Bertoni, R. et al. (1998) "Human class I supertypes and CTL repertoires extend to chimpanzees" <i>J. Immunol.</i> <b>161</b> :4447-4455.
MD	13.	Boczkowski, D. et al. (August, 1996) "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" <i>J. Exp. Med.</i> <b>184</b> :465-472.
MD	14.	Bordignon, C. et al. (September, 1989) "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" <i>PNAS USA</i> <b>86</b> :6748-6752.
MD	15.	Carter, B.J. (1992) "Adeno-associated virus vectors" <i>Curr. Op. Biotechnol.</i> <b>3</b> :533-539.
MD	16.	Caruso, A. et al. (1997) "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" <i>Cytometry</i> <b>27</b> :71-76.
MD	17.	Correll, P.H. et al. (November, 1989) "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" <i>PNAS USA</i> <b>86</b> :8912-8916.

EXAMINER:

DATE CONSIDERED:

3/8/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08(2/92)  
Sheet 2 of 4

TECHNOLOGY

MAR 04 2002

Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: August 1, 2001	Group Art Unit: 1644
MO	18.	Coulie, P.G. (June, 1997) "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" <i>Molec. Med. Today</i> 3:261-268.	
MO	19.	Culver, K. et al. (April, 1991) "Lymphocytes as cellular vehicles for gene therapy in mouse and man" <i>PNAS USA</i> 88:3155-3159.	
MO	20.	Dharanipragada, R. et al. (1992) "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" <i>Acta. Cryst. C</i> 48:1239-1241.	
MO	21.	Dharanipragada, R. et al. (1993) "Synthetic linear and cyclic glucagon antagonists" <i>Int. J. Peptide Protein Res.</i> 42(1):68-77.	
MO	22.	DiMaio, J. et al. (1989) "Synthesis of chiral piperazin-2-ones as model peptidomimetics" <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689.	
MO	23.	Feltkamp, M.C.W. et al. (1995) "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" <i>Immunol. Lett.</i> 47:1-8.	
MO	24.	Ferguson, M.A.J. et al. (1988) "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" <i>Ann. Rev. Biochem.</i> 57:285-320.	
MO	25.	Fujihashi, K. et al. (1993) "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" <i>J. Immunol. Meth.</i> 160:181-189.	
MO	26.	Garvey, D.S. et al. (1990) "3,4-disubstituted $\gamma$ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" <i>J. Org. Chem.</i> 55(3):936-940.	
MO	27.	Hruby, V.J. (1982) "Conformational restrictions of biologically active peptides via amino acid side chain groups" <i>Life Sciences</i> 31(3):189-199.	
MO	28.	Hruby, V.J. et al. (1990) "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" <i>Biochem J.</i> 268:249-262.	
MO	29.	Isakov, N. et al. (January, 1995) "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" <i>J. Exp. Med.</i> 181:375-380.	
MO	30.	Jones, R.C.F., et al. (1988) "Amide bond isosteres: imidazolines in pseudopeptide chemistry" <i>Tetrahedron Lett.</i> 29(31):3853-3856.	
MO	31.	Kahn, M. et al. (1989) "The incorporation of $\beta$ -turn prosthetic units into merrifield solid phase peptide synthesis" <i>Tetrahedron Lett.</i> 30(18):2317-2320.	
MO	32.	Karlsson, S. et al. (1986) "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" <i>The EMBO J.</i> 5(9):2377-2385.	
MO	33.	Kazmierski, W. M. et al. (1991) "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of $\alpha,\beta$ -dimethyl-phenylalanine and $\alpha,\beta$ -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" <i>Tetrahedron Lett.</i> 32(41):5769-5772.	
MO	34.	Kazmierski, W.M. et al. (1991) "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" <i>J. Am. Chem. Soc.</i> 113:2275-2283.	
MO	35.	Kemp, D.S. et al. "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent $\beta$ -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50:5834-5838.	
MO	36.	Kemp, D.S. et al. (1988) "Conformational analysis of peptide-functionalized diacylaminoepindolidiones $^1H$	
EXAMINER:		DATE CONSIDERED: 3/18/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

PTO/SF 08 (2/98)  
Sheet 3 of 3

TECHNICAL CENTER 1600/2800

RECEIVED

Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
		Filing Date: August 1, 2001	Group Art Unit: 1644
(use several sheets if necessary)			
NMR evidence for $\beta$ -sheet formation" <i>Tetrahedron Lett.</i> 29(40):5081-5082.			
37.	Kemp, D.S. et al. (1988) "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diazacyclodeca-2, 7-dione The dilactam of L- $\alpha$ , $\gamma$ -diaminobutyric acid and D-glutamic acid: A $\beta$ -turn template" <i>Tetrahedron Lett.</i> 29(40):5057-5060.		
38.	Kemp, D.S. et al. (1988) "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 <sup>4,8</sup> ]-ridecane, 1 the preferred conformation of 1 (1= $\alpha$ temp-OH) and its peptide conjugates $\alpha$ temp-L-(Ala) <sub>n</sub> -OR (n=1 to 4) and $\alpha$ -temp -L-Ala-L-Phe-Lys( $\epsilon$ Boc)-L-Lys( $\epsilon$ -Boc)-NHMe studies of templates for $\alpha$ -helix formation" <i>Tetrahedron Lett.</i> 29(39):4935-4938.		
39.	Kemp, D.S. et al. (1989) "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as $\gamma$ -turn templates" <i>J. Org. Chem.</i> 54:109-115.		
40.	McGrory, W.J. et al. (1988) "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" <i>Virology</i> 163:614-617.		
41.	Merrifield, R.B. (1967) "New approaches to the chemical synthesis of peptides" <i>Recent Progress in Hormone Res.</i> 23:451-482.		
42.	Miyake, A. et al. (1984) "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" <i>J. Takeda Res. Labs.</i> 43(3/4):53-76.		
43.	Mosier, D.E. et al. (March, 1993) "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" <i>PNAS. USA</i> 90:2443-2447.		
44.	Muzyczka, N. (1992) "Use of adeno-associated virus as a general transduction vector for mammalian cells" <i>Curr. Top. Microbiol. Immunol.</i> 158:97-129.		
45.	Nagai, U. et al. (1985) "Synthesis of a bicyclic dipeptide with the shape of $\beta$ -turn central part" <i>Tetrahedron Lett.</i> 26(5):647-650.		
46.	Nair, S. et al. (February, 1992) "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" <i>J. Exp. Med.</i> 175:609-612.		
47.	Olson, G.L. et al. (1990) "Design and synthesis of a protein $\beta$ -turn mimetic" <i>J. Am. Chem. Soc.</i> 112:323-333.		
48.	Paglia, P. et al. (January, 1996) "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" <i>J. Exp. Med.</i> 183:317-322.		
49.	Pardoll, D.M. (1998) "Cancer vaccines" <i>Nature Med.</i> 4(5 Suppl.):525-531.		
50.	Parker, K.C. et al. (1992) "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" <i>J. Immunol.</i> 149(11):3580-3587.		
51.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14:34-57.		
52.	Parkhurst, M.R. et al. (1996) "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" <i>J. Immunol.</i> 157:2539-2548.		
53.	Rill, D.R. et al. (May 15, 1992) "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" <i>Blood</i> 79(10):2694-2700.		
54.	Rouse, R.J.D. et al. (September, 1994) "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" <i>J. Virol.</i> 68(9):5685-5689.		

EXAMINER:

DATE CONSIDERED:

3/18/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



PTO/SB/08 (2/92)


Sheet 4 of 4

Form PTO-1449	Docket No. GZ 2063.10	Appl. No. 09/920,480
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: August 1, 2001	Group Art Unit: 1644
55.	Salazar, E. et al. (2000) "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" <i>Int. J. Cancer</i> 85:829-838.	
56.	Samanen, J. et al. (1990) "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted conformation" <i>Int. J. Peptide Protein Res.</i> 35:501-509.	
57.	Schlesinger, S. et al. (1999) "Alphavirus vectors for gene expression and vaccines" <i>Curr Opin Biotechnol.</i> 10(5):434-439.	
58.	Sette, A. et al. (1994) "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" <i>J. Immunol.</i> 153(12):5586-5592.	
59.	Shirai, M. et al. (1995) "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" <i>J. Immunol.</i> 154:2733-2742.	
60.	Stuber, G. et al. (1995) "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" <i>Int. Immunol.</i> 7(4):653-663.	
61.	Tan, L. et al. (1997) "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" <i>J. Immunol. Meth.</i> 209(1):25-36.	
62.	Tanguay, S. et al. (1994) "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" <i>Lymphokine Cytokine Res.</i> 13(4):259-263.	
63.	Valmori, D. et al. (2000) "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" <i>J. Immunol.</i> 164(2):1125-1131.	
64.	van der Burg, S.H. et al. (1996) "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" <i>J. Immunol.</i> 156:3308-3314.	
65.	Ware, C.F. et al. (1983) "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" <i>J. Immunol.</i> 131(3):1312-1317.	
66.	Wilchek, M. et al. (1988) "The avidin-biotin complex in bioanalytical applications" <i>Anal. Biochem.</i> 171:1-32.	
67.	Ying, H. et al. (July 19, 1999) "Cancer therapy using a self-replicating RNA vaccine" <i>Nat. Med.</i> 5(7):823-827.	
68.	Zabrocki, J. et al. (1988) "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" <i>J. Am. Chem. Sci.</i> 110:5875-5880.	
69.	Zechel, C. et al. (1991) "Synthetic glucagon antagonists and partial agonists" <i>Int. J. Pep. Protein Res.</i> 38(2):131-138.	
70.	Zweerink, H.J. et al. (March 1, 1993) "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" <i>J. Immunol.</i> 150(5):1763-1771.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



+ GP/1644

Substitute for form 449A-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	09/920,480
Filing Date	August 1, 2001
First Named Inventor	Charles A NICOLETTE
Art Unit	1644
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2063.10

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
MD	1	US-5,695,937	12/9/97	Kinzler et al.	
MD	2	US-5,869,445	2/9/99	Cheever, et al.	
MD	3	US-6,028,059	2/22/00	Curiel, et al.	
MD	4	US-5,844,075 (*)	12/1/98	Kawakami et al.	

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	5	FR 2,757,169	6/19/98	Institute Natl de la Sante et de la Recherche Medical InsermEtabliss Public a Caract Scient et Tech		
MD	6	WO 99/02183	1/21/99	CTL Immunotherapies Corp.		
MD	7	WO 00/20457	4/13/00	Genzyme Corp.		
MD	8	WO 97/35035 (*)	3/20/97	Genzyme Corp.		

Examiner's  
Signature

*Marianne D.*


Date  
Considered

3/18/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449B-P

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	09/920,480
Filing Date	August 1, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1644
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2063.10

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	1	ALEXANDER-MILLER et al. "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" <i>PNAS USA</i> (1996) 93(9):4102-4107 (*)	
	2	BLOOM et al. "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16 melanoma" <i>J. Exp. Med</i> (1997) 185(3):453 (*)	
	3	BORCHARDT et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" <i>Chem. Biol.</i> (1997) 4(12):961-968 (*)	
	4	BOUCHARD et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells" <i>Eur. J. Biochem</i> (1994) 219(1-2):127-134 (*)	
MD	5	COCKLE, S.M., et al. "Thyrotrophin-releasing hormone-related polypeptides in rabbit prostate and semen are different from those in rabbit hypothalamus" <i>J. Endocrinology</i> (1989) 120: 31-36	
	6	COLACO "Why are dendritic cells central to cancer immunotherapy?" <i>Mol. Med.</i> (January 1999) Today:14-17 (*)	
MD	7	FISK, B. et al. "Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implications for Optimization of antigen presentation and tumor-specific CTL induction" <i>Immunol.</i> (1996) 18(4):197-209	
MD	8	FORBES, J.F. "The incidence of breast cancer: The global burden, public health considerations" <i>Seminars in Oncology</i> (1997) 24(1), Suppl. 1. pp. S1-20-S1-35	
	9	GISH et al., "Identification of protein-coding regions by database similarity search" <i>Nature Genetics</i> (1993) 3:266-273 (*)	
MD	10	GREENLEE, R.T. et al. "Cancer Statistics, 2001" . <i>CA Cancer J Clin</i> (2001) 51(1):15-36	
MD	11	KAWAKAMI et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS USA</i> (1994) 91:6458-6462 (*)	
MD	12	KAWAKAMI, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" <i>PNAS USA</i> (1994) 91(9):3515-3519 (*)	
MD	13	KUHNS, J.J. et al. "Poor Binding of a HER-2/neu Eptope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide" <i>J. Biol. Chem.</i> (1999) 274:36422-36427	
MD	14	LINDAUER et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" <i>J. Mol. Med.</i> (1998) 76:32-47 (*)	
MD	15	LOCKHART, D.J. and E.A. WINZELER "Genomics, gene expression and DNA arrays" <i>Nature</i> (2000) 405:827-836	
MD	16	RIES, L.A. et al. "The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer" <i>Cancer</i> (2000) 88(10):2398-2424	
MD	17	RONGEUN, Y. et al. "Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas" <i>J. Immunol.</i> (1999) 163:1037-1044	
	18	ROSENBERG et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" <i>Nature Med.</i> (1998) 4(3):321-327 (*)	
	19	SALGALLER et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides" <i>Cancer Res.</i> (1995) 55:4972-4979 (*)	
	20	SCHENA et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>PNAS USA</i> (1996) 93:10614-10619 (*)	

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

cm. a 3/18/04

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner's  
Signature**

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

Form PTO-1449			Docket No. GZ-2063.10		Appl. No. 09/920,480	
<b>INFORMATION DISCLOSURE STATEMENT</b>			Applicant(s) <div style="text-align: right;">Charles A. NICOLETTE</div>			
(use several sheets if necessary)			Filing Date: August 1, 2001		Group Art Unit: 1644	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Filing Date (if appropriate)
	1.					
	2.					
	3.					
	4.					
	5.					
	6.					
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass
MD	7.	11/02/95	WO 95/29193	The Government of the United States of America		
<b>OTHER DOCUMENTS</b>						
Examiner Initials	Ref. No.	Title <small>(including author, title, date, pertinent pages, etc.)</small>				
	8.					
	9.					
	10.					
	11.					
	12.					
	13.					
	14.					
	15.					
	16.					
	17.					
	18.					
	19.					
	20.					
	21.					
	22.					
	23.					
	24.					
	25.					
	26.					

EXAMINER: <i>Marianne J. [Signature]</i>	DATE CONSIDERED: <i>3/17/01</i>
<small>EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.</small>	

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number 159792006300	Application Number 09/249,272
	Applicant Charles A. NICOLETTE	
	Filing Date February 11, 1999	Group Art Unit 1648

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
MD	1.	03/20/97	WO 97/35035	Nicolette			

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
MD	2.	Alexander-Miller et al., "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" <i>PNAS USA</i> 93(9):4102-4107 (1996).
	3.	Bloom et al., "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16 melanoma" <i>J. Exp. Med.</i> 185(3):453 (1997).
	4.	Borchardt et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" <i>Chem. Biol.</i> 4(12):961-968 (1997).
	5.	Bouchard et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells" <i>Eur. J. Biochem.</i> 219(1-2):127-134 (1994).
	6.	Colaco, "Why are dendritic cells central to cancer immunotherapy?" <i>Mol. Med. Today</i> :14-17 (January 1999).
	7.	Gish et al., "Identification of protein coding regions by database similarity search" <i>Nature Genetics</i> 3:266-273 (1993).
	8.	Kawakami et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" <i>PNAS USA</i> 91(9):3515-3519 (1994).
	9.	Kawakami et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS USA</i> 91:6458-6462 (1994).
	10.	Lindauer et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" <i>J. Mol. Med.</i> 76:32-47 (1998).
MD	11.	Pardoll, "Cancer vaccines" <i>Nature Med. Vaccine Supp.</i> 4(5):525-531 (May 1998).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number 159792006300	Application Number 09/249,272 09/249,272
	Applicant Charles A. NICOLETTE	
	Filing Date February 11, 1999	Group Art Unit 1648 1644

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
MO	12.	Rosenberg et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" <i>Nature Med.</i> 4(3):321-327 (1998).
	13.	Salgaller et al. "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides" <i>Cancer Res.</i> 55:4972-4979 (1995).
	14.	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>PNAS USA</i> 93:10614-10619 (1996).
	15.	Shepherd et al., "Preparation and screening of an arrayed human genomic library generated with the P1 cloning system" <i>PNAS USA</i> 91:2629-2633 (1994).
	16.	Tam, "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system" <i>PNAS USA</i> 85:5409-5413 (1998).
	17.	Türeci et al., "Serological analysis of human tumor antigens: Molecular definition and implications" <i>Mol. Med. Today</i> 3(8):342-349 (August 1997).
	18.	Zhai et al., "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100" <i>J. Immunol.</i> 20(1):15-25 (1997).
MO	19.	Zügel et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" <i>J. Immunol.</i> 161:1705-1709 (1998).

EXAMINER:

M. N. [Signature]

DATE CONSIDERED:

3/8/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

